Target Price | $316.39 |
Price | $280.35 |
Potential | 12.86% |
Number of Estimates | 23 |
23 Analysts have issued a price target Amgen 2026 . The average Amgen target price is $316.39. This is 12.86% higher than the current stock price. The highest price target is $400.00 42.68% , the lowest is $215.00 23.31% . | |
A rating was issued by 33 analysts: 16 Analysts recommend Amgen to buy, 15 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2026 of 12.86% . Most analysts recommend the Amgen stock at Purchase. |
26 Analysts have issued a sales forecast Amgen 2025 . The average Amgen sales estimate is $35.3b . This is 3.38% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $35.9b 5.32% , the lowest is $34.5b 1.19% .
This results in the following potential growth metrics:
2024 | $33.4b | 18.57% |
---|---|---|
2025 | $35.3b | 5.55% |
2026 | $35.9b | 1.87% |
2027 | $37.1b | 3.21% |
2028 | $37.5b | 1.13% |
2029 | $38.4b | 2.48% |
11 Analysts have issued an Amgen EBITDA forecast 2025. The average Amgen EBITDA estimate is $17.2b . This is 21.02% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $21.4b 51.16% , the lowest is $12.8b 9.44% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $15.3b | 85.55% |
---|---|---|
2025 | $17.2b | 12.59% |
2026 | $17.3b | 0.73% |
2027 | $17.7b | 2.26% |
2028 | $18.8b | 6.58% |
2029 | $18.6b | 1.56% |
2024 | 45.63% | 56.49% |
---|---|---|
2025 | 48.67% | 6.67% |
2026 | 48.13% | 1.11% |
2027 | 47.68% | 0.93% |
2028 | 50.25% | 5.39% |
2029 | 48.27% | 3.94% |
9 Amgen Analysts have issued a net profit forecast 2025. The average Amgen net profit estimate is $7.2b . This is 21.71% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $8.3b 40.20% , the lowest is $6.6b 11.38% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.1b | 39.11% |
---|---|---|
2025 | $7.2b | 76.56% |
2026 | $7.7b | 6.47% |
2027 | $8.5b | 10.33% |
2028 | $10.5b | 23.90% |
2029 | $12.1b | 15.13% |
2024 | 12.24% | 48.64% |
---|---|---|
2025 | 20.47% | 67.28% |
2026 | 21.39% | 4.49% |
2027 | 22.87% | 6.92% |
2028 | 28.02% | 22.52% |
2029 | 31.48% | 12.35% |
9 Analysts have issued a Amgen forecast for earnings per share. The average Amgen EPS is $13.43 . This is 22.54% higher than earnings per share in the financial year 2024. The highest EPS forecast is $15.47 41.15% , the lowest is $12.29 12.14% .
This results in the following potential growth metrics and future valuations:
2024 | $7.56 | 39.47% |
---|---|---|
2025 | $13.43 | 77.65% |
2026 | $14.30 | 6.48% |
2027 | $15.78 | 10.35% |
2028 | $19.55 | 23.89% |
2029 | $22.50 | 15.09% |
Current | 25.58 | 41.81% |
---|---|---|
2025 | 20.87 | 18.41% |
2026 | 19.61 | 6.04% |
2027 | 17.77 | 9.38% |
2028 | 14.34 | 19.30% |
2029 | 12.46 | 13.11% |
Based on analysts' sales estimates for 2025, the Amgen stock is valued at an EV/Sales of 5.65 and an P/S ratio of 4.27 .
This results in the following potential growth metrics and future valuations:
Current | 5.84 | 21.51% |
---|---|---|
2025 | 5.65 | 3.26% |
2026 | 5.55 | 1.83% |
2027 | 5.37 | 3.11% |
2028 | 5.31 | 1.12% |
2029 | 5.19 | 2.42% |
Current | 4.42 | 21.09% |
---|---|---|
2025 | 4.27 | 3.27% |
2026 | 4.19 | 1.83% |
2027 | 4.06 | 3.11% |
2028 | 4.02 | 1.12% |
2029 | 3.92 | 2.42% |
Analyst | Rating | Action | Date |
---|---|---|---|
Cantor Fitzgerald |
Neutral
➜
Neutral
|
Unchanged | Jun 24 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | May 16 2025 |
Mizuho |
Neutral
➜
Neutral
|
Unchanged | May 07 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | May 02 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | May 02 2025 |
Cantor Fitzgerald |
➜
Overweight
|
Initiated | Apr 22 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Apr 14 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Cantor Fitzgerald:
Neutral
➜
Neutral
|
Jun 24 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
May 16 2025 |
Unchanged
Mizuho:
Neutral
➜
Neutral
|
May 07 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
May 02 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
May 02 2025 |
Initiated
Cantor Fitzgerald:
➜
Overweight
|
Apr 22 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Apr 14 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.